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Background:  It  has  been  well  known  that  the inhibition  of  platelet  aggregation  (IPA) by  anti-platelet  agents
was  important  to  reduce  the  thrombo-embolic  events  in  patients  with  ST segment  elevation  myocardial
infarction  (STEMI).  However,  the  peri-procedural  IPA by anti-platelet  agents  was  not well known.
Methods:  We  compared  the  peri-procedural  IPA  between  prasugrel  and adjunctive  cilostazol  to  dual
anti-platelet  therapy  (triple  anti-platelet  therapy;  TAP)  in patients  with  STEMI  undergoing  primary  per-
cutaneous  coronary  intervention  (PCI).  We  prospectively  randomized  70 consecutive  clopidogrel-naive
patients  with  STEMI  planned  PCI  to  either  prasugrel  [loading  dose  (LD)  60 mg; 37  patients]  or  TAP  (LD
aspirin  300  mg,  clopidogrel  600  mg,  and  cilostazol  200  mg;  33  patients).  Primary  end  points  of  the  study
were  the  platelet  reactivity  unit  (PRU)  or % inhibition  by  the  VerifyNow  P2Y12 assay  at  pre-PCI and
pre-discharge.
Results:  The  drug  loading  to  pre-PCI  time  was  similar  between  prasugrel  and  TAP  groups  (25.4 ±  10.42 min
vs. 25.5  ±  10.56  min,  p  = 0.957).  PRU at pre-PCI  was signiﬁcantly  lower  in prasugrel  than  in TAP
(269.1  ±  71.69  vs. 306.5  ±  48.67, p = 0.012).  The  lower  PRU and  greater  %  inhibition  also  observed  in
prasugrel  than  in  TAP  at pre-discharge  (108.2  ± 60.51  vs. 238.1  ± 73.40;  63.6  ± 18.51%  vs.  16.8  ±  17.91%,
p <  0.001  respectively).  No differences  in  in-hospital  bleeding  complications  between  the two  groups
were  observed.
Conclusion:  Our  study  demonstrates  that  prasugrel  could  produce  a signiﬁcantly  greater  peri-procedural
 comp
©  2as  well  as  in-hospital  IPA
ntroduction
Even though the treatments for patients with ST-segment ele-
ation myocardial infarction (STEMI) have improved over the past
ecades, it remains the most common cause of death and is mainly
aused by thrombotic occlusion. For reduction of infarct size and
ortality, the optimal inhibition of platelet aggregation (IPA) by
nti-platelet agents and primary percutaneous coronary interven-
ion (PCI) should be performed as soon as possible. European
ociety of Cardiology (ESC) Guidelines for the management of
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patients with STEMI recommended that if the patient presents
early, with a large amount of myocardium at risk or directly to a PCI-
capable hospital, primary PCI should be performed within 60 min of
ﬁrst medical contact [1]. Therefore, the faster PCI patients undergo
treatment, the faster onset of anti-platelet effect patients should be
needed to achieve.
The ADP receptor inhibitor prasugrel has a faster and more
potent IPA than clopidogrel by a different primary metabolic path-
way [2]. The addition of cilostazol to aspirin and clopidogrel (triple
anti-platelet therapy; TAP) also has a signiﬁcantly greater IPA
and better clinical outcomes compared with dual anti-platelet
agents in patients with acute myocardial infarction [3]. However,
peri-procedural IPA by prasugrel and TAP have not been stud-
ied in patients with STEMI. Therefore, the purpose of this study
was to compare the peri-procedural and in-hospital IPA between
prasugrel and TAP in patients with STEMI undergoing primary
PCI.
llege of Cardiology.
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aterials and methods
tudy population and protocol
From March to November 2012, we enrolled consecutive
lopidogrel-naive patients with STEMI-planned PCI at Chonnam
ational University Hospital. We  excluded the patients who pre-
ented with cardiogenic shock at admission and with a history
f previous PCI or bypass surgery, transient ischemic attack or
erebrovascular accidents (CVA), and a bleeding disorder. We
mmediately randomized the enrolled patients to either prasug-
el or TAP in the emergency room. All patients received the loading
ose (LD) of aspirin 300 mg  followed by maintenance dose (MD) of
00 mg/day during hospitalization. Prasugrel was  given as 60 mg
D followed by 10 mg/day or 5 mg/day MD when the patient was
ore than 75 years or less than 60 kg, whereas TAP group was
dministered a LD of 600 mg  clopidogrel and 200 mg  cilostazol fol-
owed by MD  of clopidogrel 75 mg/day and cilostazol 200 mg/day.
fter administration of LD of anti-platelet agents in the emergency
oom, the patient was sent to the cardiac catheterization room
s soon as possible, and received coronary angiography and PCI.
he primary PCI was performed in a routine manner. The vascu-
ar access, manual aspiration thrombectomy, and the type of stents
ere determined based on the decision of operators. Glycoprotein
Ib/IIIa inhibitors were used as an only bail-out therapy during the
rocedure in situations of large thrombi or no reﬂow. After the
ntervention, all patients took 300 mg  of aspirin per day and the MD
f the anti-platelet agents of the study group to which they belong
uring hospitalization. Other medical treatments were also used
ased on the standard treatment regimen for patients with STEMI
n a non-restrictive manner. We  performed the platelet function
ssay twice during hospitalization, at pre-PCI and pre-discharge.
re-PCI was deﬁned as the time just before wiring for target lesion
uring primary PCI and pre-discharge, as the hospital discharge day
r commonly 5 days after primary PCI. A ﬂow chart diagram of our
tudy is shown in Fig. 1.latelet function assay
The ﬁrst 2–4 ml  of blood was discarded to avoid spontaneous
latelet activation, and blood samples were collected in 2.7 mLrcutaneous coronary intervention.
BD Vacutainer® plastic whole blood tube with 3.2% sodium citrate
(Becton, Dickinson & Co., Plymouth, UK). Then, platelet function test
was performed immediately using the VerifyNow® (Accumetrics
Inc., San Diego, CA, USA) point-of-care P2Y12 function assay. The
results are expressed in P2Y12 reaction units (PRU). The VerifyNow®
P2Y12 assay also determines the percentage of platelet inhibition (%
PI) by the anti-platelet agents using PRU and baseline PRU values. It
is well known that the VerifyNow® P2Y12 assay correlated strongly
with inhibition of P2Y12 function, as measured with the “gold
standard” of light transmission aggregometry (LTA) in patients
treated with prasugrel or clopidogrel [4]. The high on-treatment
platelet reactivity (HTPR) was considered as a value ≥235 PRU [5].
Endpoints
The primary endpoint was  a PRU or % PI at pre-PCI and pre-
discharge between the two  groups. The secondary endpoint was a
composite of cardiac death, non-fatal MI,  CVA, and stent throm-
bosis. Stent thrombosis was deﬁned according to the Academic
Research Consortium deﬁnition. We  also compared the incidence
of thrombolysis in myocardial infarction (TIMI) major or minor
bleeding during hospitalization in both groups [6].
Statistical analysis
Categorical variables were expressed as a frequency and con-
tinuous variables as mean ± SD (standard deviation). An analysis
of categorical variables was  performed using chi-square test or
Fisher’s exact test and that of continuous ones using Student’s t-
test. The mean PRU among 3 groups were compared by one-way
ANOVA with post hoc analysis for multiple comparisons. All tests
were 2-tailed and statistical signiﬁcance was  considered for p-
values <0.05. All the statistical analyses were performed using SPSS
(Statistical Package for Social Science, SPSS Inc., Chicago, IL, USA)
for Windows, Version 18.0.
Sample size calculationThere were no available data about PRU at acute phase in both
prasugrel and TAP. However, according to the results of ACCEL-AMI
and TIMI 44 trial [3,7], we  could hypothesize that prasugrel would
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Table  1
Baseline clinical characteristics and in-hospital medications.
Prasugrel (n = 37) TAP (n = 33) p-Value
Age, years 59.4 ± 10.30 64.3 ± 13.17 0.063
Male gender 31 (83.8) 23 (69.7) 0.161
Hypertension 13 (35.1) 16 (48.5) 0.258
Diabetes mellitus 12 (32.4) 12 (36.4) 0.729
Dyslipidemia 5 (13.5) 3 (9.1) 0.714
Current smoker 22 (59.5) 16 (48.5) 0.358
Family history of coronary
artery disease
0 (0.0) 1 (3.0) 0.471
History of angina 0 (0.0) 0 (0.0) 1.000
Prior use of aspirin 3 (8.1) 1 (3.0) 0.616
Prior use of
thienopyridines
0 (0.0) 0 (0.0) 1.000
Killip class 0.313
I  28 (75.7) 21 (63.6)
II  1 (2.7) 5 (15.2)
III  5 (13.5) 4 (12.1)
IV  3 (8.1) 3 (9.1)
Left ventricular ejection
fraction, %
53.8 ± 9.71 49.4 ± 9.00 0.050
Creatinine clearance,
ml/min/1.73 m2
83.9 ± 36.13 82.3 ± 26.88 0.839
Body mass index, kg/m2 24.0 ± 3.49 24.2 ± 3.64 0.888
In-hospital medications
Aspirin 37 (100.0) 33 (100.0) 1.000
Beta-blockers 30 (81.1) 29 (87.9) 0.522
Angiotensin II receptor
blockers
27 (73.0) 28 (84.8) 0.227
Statin 34 (91.9) 31 (93.9) 1.000
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Table 2
Laboratory ﬁndings.
Prasugrel (n = 37) TAP (n = 33) p-Value
Hemoglobin, g/dl 14.5 ± 1.68 13.8 ± 2.13 0.129
White blood cell, ×103/mm3 10.9 ± 3.29 12.1 ± 3.24 0.130
Platelet, ×103/mm3 252.5 ± 73.14 236.8 ± 55.72 0.322
Glucose, mg/dl 190.0 ± 65.96 198.6 ± 98.46 0.668
Creatinine, mg/dL 0.88 ± 0.23 0.94 ± 0.25 0.290
Total cholesterol, mg/dL 187.4 ± 35.24 186.7 ± 45.50 0.942
LDL-cholesterol, mg/dL 119.4 ± 37.40 123.6 ± 40.38 0.658
HDL-cholesterol, mg/dL 42.2 ± 10.05 41.7 ± 12.70 0.844
Triglyceride, mg/dL 169.7 ± 157.30 125.8 ± 84.90 0.163
Peak CK, U/L 842.3 ± 1259.96 1201.9 ± 1467.44 0.274
Peak CK-MB, U/L 201.5 ± 103.81 208.5 ± 147.38 0.818
Peak troponin-I, ng/ml 102.1 ± 94.37 103.2 ± 92.20 0.963
hs-CRP, mg/dL 0.6 ± 1.43 1.7 ± 3.30 0.087
rel MD  (95.4 ± 58.70 vs. 148.0 ± 49.88, p = 0.096), however, it was
still signiﬁcantly lower than that with TAP (Fig. 3). Lower rates of
HTPR at pre-PCI were observed with prasugrel compared with TAP
(67.6% vs. 93.9%, p = 0.007). At pre-discharge, the rate of HTPR with
Table 3
Procedural characteristics.
Prasugrel (n = 37) TAP (n = 33) p-Value
Trans-radial intervention 9 (24.3) 10 (30.3) 0.574
Infarct-related artery 0.554
Left anterior descending artery 21 (56.8) 17 (51.5)
Left circumﬂex artery 3 (8.1) 5 (15.2)
Right coronary artery 13 (35.1) 10 (30.3)
Left main 0 (0.0) 1 (3.0)
Involved vessel number 0.589
Single vessel 23 (62.2) 23 (69.7)
Two  vessel 10 (27.0) 6 (18.2)
Three vessel 4 (10.8) 3 (9.1)
Left main disease (simple) 0 (0.0) 1 (3.0)
ACC/AHA classiﬁcation 0.462
Type B2 34 (91.9) 28 (84.8)
Type C 3 (8.1) 5 (15.2)
Type of stent used 0.979
Everolimus-eluting stents 19 (51.4) 18 (48.6)
Biolimus-eluting stents 13 (35.1) 10 (30.3)
Zotarolimus-eluting stents 3 (8.1) 3 (9.1)
Bare metal stents 2 (5.4) 2 (6.1)
Number of stents at target lesion 1.30 ± 0.57 1.18 ± 0.39 0.159
Stent diameter at target lesion 3.19 ± 0.45 3.13 ± 0.31 0.390
Stent length at target lesion 25.51 ± 7.50 23.91 ± 7.99 0.323
Pre-PCI TIMI antegrade ﬂow 0.616
0  26 (70.3) 22 (66.7)
I  2 (5.4) 4 (12.1)
II  7 (18.9) 4 (12.1)
III  2 (5.4) 3 (9.1)
Post-PCI TIMI antegrade III ﬂow 35 (94.6) 33 (100.0) 0.494
Use  of glycoprotein IIb/IIIa
inhibitor
5 (13.5) 6 (18.2) 0.592
Thrombus aspiration 92 (24.3) 9 (27.3) 0.778
Use  of temporary pacemaker 6 (16.2) 3 (9.1) 0.485
Use  of IABP 1 (2.7) 3 (9.1) 0.337
Symptom to door time, min  351.5 ± 613.05 479.3 ± 876.70 0.478
Door to balloon time, min 59.0 ± 23.14 57.5 ± 13.92 0.740
Drug loading to pre-PCI time, min  25.4 ± 10.42 25.5 ± 10.56 0.957Omega-3 4 (10.8) 3 (9.1) 1.000
ata are n (%), or mean ± SD. TAP, triple anti-platelet therapy.
e superior to TAP with a difference of 38.5% PI by VerifyNow®
2Y12 assay at maintenance phase. Choosing a 2-sided a-level of
.01, power of 95%, a standard deviation of 0.30 and a 1:1 random-
zation, we will need a total of 46 subjects (at least 23 in each group)
o be able to reject the null hypothesis that the population means
f both groups are equal with power of 95%. The Type I error prob-
bility associated with this test of this null hypothesis is 0.01. In
pite of the result of sample size calculation, at the beginning of our
tudy, we planned to randomize a total of 100 patients with STEMI.
owever, the enrollment was interrupted by 70 patients due to
ufﬁcient numbers to compare IPA between two groups. The study
rotocol was approved by the institutional review board (CNUH-
011-221), and all patients provided written informed consent for
articipation.
esults
We  randomized 70 consecutive clopidogrel-naive patients with
TEMI planned PCI to either prasugrel (37 patients) or TAP (33
atients). Baseline clinical, laboratory, and procedural character-
stics of the two groups are shown in Tables 1–3. There were no
igniﬁcant differences in any baseline characteristics between the
wo groups.
The drug loading to pre-PCI and door to balloon times
ere also similar between the two groups (25.4 ± 10.42 min  vs.
5.5 ± 10.56 min, p = 0.957; 59.0 ± 23.14 min  vs. 57.5 ± 13.92 min,
 = 0.740) (Table 3). All patients underwent platelet function test
y the VerifyNow® P2Y12 assay at pre-PCI and pre-discharge.
PRU at pre-PCI was signiﬁcantly lower in the prasugrel group
han in the TAP group (269.1 ± 71.69 vs. 306.5 ± 48.67, p = 0.012)
nd % inhibition at pre-PCI tended to be higher with prasugrel than
AP (2.6 ± 9.78% vs. 0.0 ± 0.00%, p = 0.119). At discharge, prasugrel
till had lower PRU and greater % inhibition than TAP (108.2 ± 60.51
s. 238.1 ± 73.40; 63.6 ± 18.51% vs. 16.8 ± 17.91%, p < 0.001, respec-
ively) (Fig. 2 and Table 4). The PRU in the 5-mg prasugrel MD (n = 9)Data are mean ± SD. TAP, triple anti-platelet therapy; LDL, low-density lipopro-
tein; HDL, high-density lipoprotein; CK, creatine kinase; hs-CRP, high sensitivity
C-reactive protein.
at discharge tended to be higher than that in the 10-mg prasug-Data are n (%), or mean ± SD. TAP, triple anti-platelet therapy; CAD, coronary artery
disease; PCI, percutaneous coronary intervention; ACC/AHA, American College of
Cardiology/American Heart Association; TIMI, Thrombolysis In Myocardial Infarc-
tion; IAPB, intra-aortic balloon pump.
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2Y12 assay at pre-PCI and pre-discharge in patients treated with prasugrel (white)
edian  and error bars the values of the lower and upper quartiles.
rasugrel was 0.0%, however, that in TAP was 54.5%, which is still
igh (Fig. 4).
During hospitalization, cardiac death, non-fatal MI,  or stent
hrombosis did not occur in either group, however, 1 patient in the
AP group suffered from CVA after 2nd stage PCI for non-culprit
esion. TIMI major bleeding such as a fall in hemoglobin of >5 g/dL
eveloped in 1 patient in the TAP group and minor bleeding in 2
atients on TAP. However, no fatal bleeding complications devel-
ped in either group (Table 4).iscussion
Our study is the ﬁrst to compare the PRU by VerifyNow® P2Y12
ssay at both pre-PCI and pre-discharge between prasugrel and
able 4
he platelet reactivity and in-hospital clinical outcomes.
Prasugrel (n = 37) TAP (n = 33) p-Value
PRU at pre-PCI 269.1 ± 71.69 306.5 ± 48.67 0.012
%  platelet inhibition at pre-PCI 2.6 ± 9.78 0.0 ± 0.00 0.119
PRU  at pre-discharge 108.2 ± 60.51 238.1 ± 73.40 <0.001
%  platelet inhibition at pre-discharge 63.6 ± 18.51 16.8 ± 17.91 <0.001
Cardiogenic shock 6 (16.2) 5 (15.2) 0.903
AVB requiring temporary pacemaker 3 (8.1) 1 (3.0) 0.616
Ventricular tachycardia/ﬁbrillation 2 (5.4) 2 (6.1) 1.000
TIMI major bleeding 0 (0.0) 1 (3.0) 0.471
TIMI minor bleeding 0 (0.0) 2 (6.1) 0.219
Cardiac death 0 (0.0) 0 (0.0) 1.000
Non-fatal myocardial infarction 0 (0.0) 0 (0.0) 1.000
Cerebro-vascular accident 0 (0.0) 1 (3.0) 0.471
Stent thrombosis 0 (0.0) 0 (0.0) 1.000
Target vessel revascularization 0 (0.0) 0 (0.0) 1.000
Coronary artery bypass surgery 0 (0.0) 0 (0.0) 1.000
ata are n (%), or mean ± SD. TAP, triple anti-platelet therapy; PRU, platelet reactivity
nit;  PCI, percutaneous coronary intervention; AVB, atrio-ventricular block; TIMI,
hrombolysis in myocardial infarction.rge. Individual values of P2Y12 reaction units (PRU) as measured by the VerifyNow®
iple anti-platelet therapy (black) are depicted. The middle thick line represents the
TAP in patients with STEMI undergoing primary PCI. It has already
been reported that prasugrel had a higher IPA than TAP at dis-
charge [8]. Therefore, our study was  mainly aimed to compare the
peri-procedural IPA between the two groups. In our results, pra-
sugrel had a lower PRU at pre-PCI and at pre-discharge than TAP.
Consequently, our study demonstrates that prasugrel has a greater
peri-procedural as well as in-hospital IPA compared with TAP in
patients with STEMI undergoing primary PCI.
Clopidogrel is an inactive pro-drug that requires 2-step hepatic
metabolism via several cytochrome P450 enzymes (CYP2C19,
3A4/5, 1A2, 2B6, 2C9, etc.) for generation of the active metabolite
[9]. However, in real world clinical practice, it has a relatively slow
onset and low potency of PI and shows a marked inter-individual
variability in its PI [10]. Therefore, the need for new anti-platelet
agents had been raised to overcome these disadvantages of clopid-
ogrel. Some studies have reported that adding cilostazol to dual
standard anti-platelet agents (TAP) has a more potent IPA than a
high or standard MD  of clopidogrel in patients with acute MI,  or
diabetes, or clopidogrel hyporesponsiveness [3,11,12].
Prasugrel, a more recent thienopyridine is well known to have
a more rapid and potent PI than clopidogrel because of increased
effectiveness of active metabolite conversion [13,14]. In healthy
volunteers, prasugrel 60 mg  had signiﬁcantly higher mean IPA
(54%) at 30 min  after LD than clopidogrel 300 mg (3%) or 600 mg
(6%) [15]. However, our study observed the IPA at pre-PCI with
prasugrel after 60 mg  LD in patients with STEMI. In the acute phase
of STEMI, the platelet activity was  markedly increased and subse-
quently followed by platelet aggregation and propagation of the
large thrombotic burden [16,17], and these pro-coagulable condi-
tions lead to increase the risk of acute or early stent thrombosis in
patients with STEMI undergoing stent implantation [18]. Therefore,
the more rapid and potent anti-platelet agents should be needed
to reduce thrombotic complications following STEMI.
However, in our study, considering that drug loading to pre-PCI
times was about 25 min, the value of PRU and the rates of HTPR
K.-H. Park et al. / Journal of Cardiology 63 (2014) 99–105 103
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cig. 3. Platelet reactivity at pre-discharge according to maintenance dose (MD). Ind
t  pre-discharge among patients treated with 10-mg MD of prasugrel (white), 5-mg
hick  line represents the median and error bars the values of the lower and upper q
t pre-PCI with prasugrel were relatively higher in patients with
TEMI than in healthy volunteers. Although the 60 mg  prasugrel
D had a more potent IPA at pre-PCI compared to TAP, it seems
o be insufﬁcient to perfectly prevent peri-procedural thrombotic
omplications in patients with STEMI undergoing PCI. This result
ccords closely with a previous report that the anti-platelet effects
f prasugrel are delayed during the ﬁrst 2 h post-loading in patients
ith STEMI [19]. Therefore, all efforts should be made to overcome
he delayed action of anti-platelet agents whenever possible, espe-
ially during the peri-procedure period in patients with STEMI. The
revious study reported that concomitant use of prasugrel and gly-
oprotein IIb/IIIa inhibitor can help to abolish residual variability
f IPA after treatment in patients with STEMI undergoing PCI [20].
There were some data about the inﬂuence of the high LD oflopidogrel for no reﬂow phenomenon, peri-procedural MI,  or
yocardial salvage. The high 600 mg  LD of clopidogrel signiﬁcantly
educed peri-procedural MI  in patients undergoing PCI compared
ig. 4. The rates of high on-treatment platelet reactivity (HTPR) at pre-percutaneous
oronary intervention (PCI) and pre-discharge.l values of P2Y12 reaction units (PRU) as measured by the VerifyNow P2Y12 assay
f prasugrel (gray), and triple anti-platelet therapy (black) are depicted. The middle
es.
with the conventional 300 mg  LD [21]. In addition, in patients with
STEMI, pre-treatment with 600 mg  clopidogrel LD before primary
PCI was associated with a low incidence of no reﬂow phenomenon
and a reduction in the infarct size compared with a 300 mg LD
[22,23]. Although prasugrel failed to signiﬁcantly reduce maximal
creatine kinase-MB or troponin-I values in our study, we  sup-
posed that the high peri-procedural IPA by new potent anti-platelet
agents also helped to improve angiographic results and myocardial
salvage.
Bleeding complications are the major safety concern with pra-
sugrel and the main cause why the physicians are reluctant to use
it. However, many studies already reported that the rates of fatal
or major bleeding with prasugrel were minimal or not signiﬁcantly
different compared with those with clopidogrel in patients with
acute coronary syndrome [24–26]. Our study also showed that the
rates of bleeding complications were similar in both groups, albeit
in a small number of patients with just in-hospital follow up. The
patients with STEMI should require more potent and longer use of
anti-thrombotic agents than those with other acute coronary syn-
dromes or stable angina, and therefore were exposed to relative
high bleeding risk. However, the bleeding incidences with prasug-
rel were not as high compared with that of TAP in our study. The
appropriate selection of patients and short-term use of prasugrel
could guarantee a low incidence of bleeding complications in real
world practice.
The optimal dosage of prasugrel is also unclear, because of unre-
solved P2Y12 inhibitor therapeutic window. The lower PRU may
be associated with higher risk for early major bleeding or entry-
site complications in patients who undergo PCI [27], and these
bleeding complications were directly correlated with worse out-
comes [28,29]. A subgroup analysis of GRAVITA already reported
that a PRU < 170 was  free from 6-month ischemic events in patients
with standard-dose clopidogrel. Our study shows that PRU of a
5 mg  prasugrel MD  at discharge was  about 150, however, that of a
10 mg  prasugrel MD was  less than 100. Therefore, we consider that
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ow-dose prasugrel MD  may  be relatively reliable and safe in Korean
atients undergoing PCI and an option in patients at higher risk
or bleeding complications [30]. However, a large randomized trial
bout the safety and the optimal dosage or duration of prasugrel is
eeded.
tudy limitations
Our study had some limitations. First, we could not conduct
he VerifyNow® P2Y12 assay before drug loading in the emer-
ency room, therefore, the baseline IPA was not assessed in either
roup. However, we are sure that the IPA at pre-loading would be
ikely to be similar between the two groups, because we  random-
zed only clopidogrel-naive patients with STEMI. Second, our study
as underpowered and there was only short-term follow-up to
ssess the relationship between PRU and clinical outcomes. Third,
he VerifyNow® P2Y12 assay, instead of adenosine diphosphate
ADP)-induced LTA, or the ﬂow-cytometric vasodilator-stimulated
hosphoprotein-phosphorylation assay, was only used to evaluate
nhibition of platelet aggregation in our study. Therefore, it may  not
e sufﬁcient to fully assess the anti-platelet effect by other mech-
nisms of cilostazol. Fourth, genetic polymorphisms affecting the
rug metabolism and the factors inﬂuencing drug absorption such
s unexpected occurrence of nausea or vomiting after drug loading
ere not fully considered.
onclusion
We  demonstrate that, in patients with STEMI undergoing
rimary PCI, prasugrel could produce a signiﬁcantly greater peri-
rocedural as well as in-hospital IPA compared with TAP. However,
lbeit with usage of prasugrel, we should make an effort to more
otently inhibit platelet activity during the peri-procedure period
n patients with STEMI undergoing PCI.
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